LEP and obesity due to melanocortin 4 receptor deficiency: PTP1B, in addition to being a potential drug target for treating diabetes and obesity due to its role in downregulating insulin and leptin signalling, has also emerged as a potential therapeutic target for breast cancer treatment [43].